Pharma sector posts 40 deals worth $12 bn in June 2018

ep-pharma-sector-600

Private equity firms increase their investments in June 2018

The pharmaceutical industry reported 40 deals worth $12 billion in June 2018, as compared to five months average of 51 deals worth $33.4 billion. Private equity firms have increased their focus on the healthcare industry by contributing approximately $7 billion to the total deal value of $12 billion reported in June 2018. CVC Fund’s acquisition of majority stake in Recordati for $3.5 billion; CCRE Holdings’ proposed acquisition of remaining 94.9 per cent stake in China Biologic Products for $3.5 billion; and Roche’s proposed acquisition of remaining stake in Foundation Medicine for $2.4 billion were notable deals reported in June 2018.

20180731ep06

Private Equity Firms Increase Their Investments In June 2018

20180731ep05

20180731ep07

Venture Capital Investments Decrease In June 2018

20180731ep06

The industry reported 54 venture capital (VC) deals worth $1.6 billion in June 2018, as compared to five months average of 74 deals worth $1.9 billion. Some of the major deals in the month included I-Mab Biopharma raising $220 million in series C venture financing; Livzon Mabpharm raising $148.3 million in series.

A venture financing; and Freeline Therapeutics raising $117.3 million in series B financing.